Table 2 Effects of ketamine on primary and secondary outcomes
Outcome | No. of studies | No. of patients | Effect measure (RR or MD) | 95% CI | Probability of benefit | I2 |
|---|---|---|---|---|---|---|
Primary outcome | ||||||
Mortality at the longest follow-up available | 8 | 2978 | 0.93 | 0.79–1.08a | 83.2% |  |
Randomized controlled trials only | 7 | 2748 | 0.96 | 0.81–1.13a | 68.6% |  |
Exclusion of high risk of bias studies | 8 | 2978 | 0.93 | 0.79–1.08a | 83.2% |  |
Secondary outcome | ||||||
SOFA score | 4 | 1633 | − 0.30 | − 0.69–0.08 |  | 0% |
Vasopressor-free days (to day 28) | 4 | 1704 | 0.07 | − 0.27–0.41 |  | 67% |
Ventilator-free days (to day 28) | 4 | 1555 | 1.2 | − 1.4–3.7 |  | 55% |
Post-induction mean arterial pressure, mmHg | 2 | 929 | − 3.1 | − 6.4–0.2 |  | 0% |
Successful intubation on the first attempt | 3 | 1204 | 1.00 | 0.96–1.04 |  | 0% |